Title: Stories of patient involvement impact in Health Technology Assessments: A discussion paper

Short title (for the running head): Impact stories of patient involvement in HTA

Authors: Ann NV Single, Karen M Facey, Heidi Livingstone, Aline Silveira Silva

Name of the corresponding author: Ann Single
Mailing address: 7 Garden Grove, Ashgrove Q 4060, Australia
Telephone number: +61 434 958 390
Email address: singlehaworth@gmail.com

Acknowledgements
The authors wish to express their gratitude to Michelle Mujoomdar, Laura Weeks and Sarah Berglas at CADTH for their contribution of the CADTH case study and constructive comments on drafts of this paper. The authors are also indebted to Karen MacPherson and Naomi Fears, Healthcare Improvement Scotland, and M Sharmila A Sousa, Oswaldo Cruz Foundation (Fiocruz) School of Governance in Health at the University of Brasilia, for reviewing and providing input on the Scottish and Brazilian case studies respectively.

Sources of funding
None declared.

Authors affiliations
Ann N V Single, independent consultant, 7 Garden Grove, Ashgrove Qld 4060, Australia

Karen M Facey, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, 9 The BioQuarter, 9 Little France Road, Edinburgh, EH16 4UX, UK

Heidi Livingstone, National Institute for Health and Care Excellence, 10 Spring Gardens, London, SW1A 2BU, UK

Aline Silveira Silva, PhD student, MSc, Esplanada dos Ministérios, bl G, 70.058 900, Brazil.
Abstract

Objectives: As more health technology assessment (HTA) bodies seek to implement patient involvement, there is a desire to learn from other HTA bodies about their experiences and understand what approaches can be used and which ones make a real difference to HTA. This is difficult, as the impact of patient involvement in HTA is not well documented. This paper aims to promote further discussion about the ways in which patient involvement can impact HTAs by studying stories of impact.

Methods: In a multi-stakeholder workshop, experts leading patient involvement in four HTA bodies shared examples of HTAs where they felt patient involvement made a difference, then they reflected on these impact stories within the wider context of impact evaluation.

Results: The HTA bodies drew on patient input and patient-based evidence to inform their HTAs. The patient involvement was observed to elucidate patients’ experiences, needs and preferences which, in turn, was observed to influence the HTA recommendations about optimal use of technologies, including taking account of issues for sub-groups, outcomes that matter to patients and educational needs.

Conclusions: Personal stories of patient involvement may enable a wider understanding of different approaches to and impact of patient involvement. The examples relate to both patient input and patient-based evidence and highlight the role that patient involvement can play in reducing uncertainties and complementing the clinical and economic evidence in HTA. They suggest that impact can be seen in recommendations about how and when a technology is used.

Key words: Patient involvement; Impact; Technology Assessment
Introduction
Health technology assessment (HTA) is grounded in rigorous scientific process, focussed on quantitative methods to determine clinical, and sometimes cost, effectiveness. As it is intended to inform policy, patients have a democratic right to be involved (1). However, misunderstandings about the robustness of research into patient aspects and concerns about the biases that patients may bring, have led to slow uptake of patient involvement processes. Meanwhile HTA bodies which have implemented patient involvement processes are keen to learn from others and understand what works best and why, so that they can develop processes that suit their own context. However, few HTA bodies have published evaluations of patient involvement and been explicit about the outcome or impact of involvement (2,3,4).

The multidisciplinary and deliberative nature of HTA - in which different sources of evidence and expert opinion must work together to address a problem - means that identifying a discrete part of an HTA process, or cause for an impact, may not be simple. Along with other expert input, patient involvement is intended to inform all the elements of an HTA from shaping research questions and informing cost effectiveness models to communicating the advice or recommendations. As a result, the integration of patient views in recommendations is considered a measure of impact (5), while an increase in recommendations to reimburse or fund the cost of medicines is not (6).

This paper aims to promote further discussion about the ways in which patient involvement can impact HTAs, studying particular cases in-depth, using stories told by people who lead the practice in HTA bodies. It uses the HTA international (HTAi) definition of patient involvement in HTA and reflects on (i) patient participation in HTAs, usually taking the form of patient input, and (ii) research into patient aspects, which can be described as patient-based evidence (1). Specifically, these stories were told in response to the question of: ‘What difference is patient involvement making to your HTAs?’ and their intent was to share learnings with other HTA bodies and all HTA stakeholders.

Methods
At HTAi’s 2017 Annual Meeting, a one-day interdisciplinary workshop entitled Patient involvement in HTA – Why, when and how? was held to present and discuss the book Patient Involvement in HTA (7). An important element of this was to hear case studies or stories from HTA bodies about the value of patient involvement in their own jurisdiction.

Eight people experienced in patient involvement in HTA bodies were invited to present in one of two panels (Table 1). Four were asked to take part in a panel addressing the difference that research in patient aspects had made to an HTA and four were asked to form a panel focusing on the difference made by patient participation. Presenters were chosen because they represented different HTA bodies included as case studies in the book, although they were not necessarily an author of the case study. Rather than repeating the content of the book, which provided detailed descriptions of organizational patient involvement processes, they were asked to reflect on their personal experiences and observations of patient involvement and were given the additional prompt of ‘how or when is it adding valuing?’. Subsequently, the presenters provided personal stories or narratives of impact from the perspective of someone employed by an HTA body to make sense of the experience (8) rather than reports of formal evaluations of impact. In doing so, the stories offered their understanding of the impact of patient involvement on an HTA at the time of telling the story.
Following the workshop, each of the presenters were invited to document these observations in a paper. Four of the eight presenters - from the Scottish Health Technologies Group (SHTG), Canadian Agency for Drugs and Technologies in Health (CADTH), England’s National Institute for Health and Care Excellence (NICE) and Brazil’s National Committee for Health Technology Incorporation (CONITEC) - agreed to take part and four either declined or did not respond to the invitation. A draft paper based on notes from the presentations was prepared by one of the authors (AS). The four presenters then used this draft as an aid to further reflection on the topic, including discussions with colleagues in their organizations, and redrafted the paper accordingly.

Results
The HTA bodies included in this paper employ a variety of approaches to patient involvement, which are summarised in Table 2.

Patient-based evidence for antimicrobial wound dressings (SHTG)
SHTG, part of Healthcare Improvement Scotland, assesses non-medicine health technologies - such as devices, diagnostics and changes to treatment pathways - predominantly in rapid HTAs of clinical and cost-effectiveness. It also undertakes some full HTAs which have time scales and resources that allow it to follow the Danish model of HTA (9) that includes thorough evaluation of patient aspects and organizational issues alongside clinical and cost effectiveness.

Patient involvement in HTAs of non-medicine technologies can be challenging. Often there is no clear patient group to participate in these HTAs and patients may be unaware of the specific intervention used. However, patients’ needs, preferences, and experiences can be essential to ensure non-medicine health technologies are administered optimally.

SHTG’s HTA of antimicrobial wound dressings in patients with chronic leg ulcers (10) demonstrates the way in which patient-based evidence can provide essential evidence to formulate conclusions and develop relevant advice. SHTG found wide variability in the type of antimicrobial wound dressings used in each health board in Scotland, and uncertainty in the clinical and cost effectiveness of these dressings. To identify sufficient literature relating to patient perspectives and values, SHTG iteratively developed a literature search (11), adding terminology to capture people living with chronic wounds and any type of wound dressings.

Additionally, SHTG conducted one focus group (n=8) and six telephone interviews with people in Scotland. Thirteen of the participants had experienced chronic wound treatment with antimicrobial wound dressings and one participant was a relative of a person who had experienced the treatment. Participants were identified and recruited by a practising tissue viability nurse in a National Health Service board following ethical approval for the research. Qualitative evidence synthesis (QES) was then used to develop a comprehensive patient aspects section for the HTA report (10). This section identified patient communication and education issues, as well as outcomes of importance to patients. For example, while wound healing was the most important outcome to patients, controlling the signs and symptoms - such as odour, exudate and pain – and preventing infection and wound deterioration were also important outcomes.

This robust evidence base enabled patients’ perspectives and experiences to guide recommendations with three of the recommendations incorporating the needs and values identified in the QES. This additional evidence source also enabled HTA researchers to have sufficient evidence to develop consensus guidance and make recommendations (10).
The impact of patient involvement continued beyond publication of the recommendations as the patient-based evidence guide a short life implementation working group, the creation of a patient version of the HTA report (12) and guidance for Scotland’s National Health Service (NHS Scotland) and staff training materials. While such an outcome is persuasive of the impact and potential value of patient involvement in HTA, it also highlights the urgent need to develop this methodology so that it can be used in more rapid HTAs which account for most HTAs in Scotland.

**Patient-based evidence for obstructive sleep apnea (CADTH)**

Over the past few years, CADTH has made a concerted effort to enhance how it incorporates the patient voice within projects related to medical devices and clinical interventions (13). Direct engagement has been challenging as there are not always obvious patient groups to involve when conducting HTAs, for example when assessing diagnostic or screening interventions. As a result, CADTH has explored using QES of patient-based evidence in assessments such as the Optimal Use assessment of interventions for the treatment of obstructive sleep apnea (OSA) in adults (14).

An Optimal Use assessment aims to encourage the appropriate use of a health technology by considering the clinical and cost-effectiveness, safety, and patients’ experiences of the intervention (13). Additionally, it addresses ethical issues, implementation considerations, and any potential environmental impacts. Optimal Use assessments are reviewed by CADTH’s Health Technology Expert Review Panel for recommendation.

The QES considered the perspectives and experiences of patients, their family members, and their non-clinical caregivers about interventions for the treatment of OSA. This included positive airway pressure therapies such as continuous positive airway pressure (CPAP), oral appliances, surgical interventions and lifestyle modifications, such as diet and exercise. From the resulting thematic synthesis, two primary themes emerged. The first theme identified a range of factors that influence whether people seek and initiate treatment for OSA. For example, the review highlighted factors that might prevent people from seeking a diagnosis or starting treatment such as risk awareness and fear. It also stressed the importance of family, spouses or partners in encouraging diagnosis in the first place. The second theme reflected that all the interventions for OSA are inconvenient, uncomfortable and require considerable adaptation to daily routines. Some people living with OSA can adapt and incorporate interventions into their lives, although others cannot. This leads to low compliance despite great effort. Support of family members and caregivers again emerged as important in this process.

The QES contributed to the HTA in three major ways. First, the findings allowed for a better understanding of the clinical findings – in particular, how the interventions were used and how this could affect the assessment of the effectiveness of the intervention. In particular, the QES challenged assumptions in the context of compliance as it remains unclear whether some people do not observe a positive effect because they cannot comply with their treatment, or whether they do not comply because they do not observe a positive effect. Secondly, the synthesis informed the recommendation generated by the expert committee, i.e. people with moderate or severe OSA should first try CPAP and then if they cannot tolerate it, consider a mandibular appliance. Thirdly, the review helped to identify important implementation considerations. For example, at times there is insufficient instruction provided on how to use and care for CPAP machines or oral appliances which can affect compliance and effectiveness.

Recognition of the added value of QES of patient aspects has resulted in its wider use in CADTH and an understanding that the influence of patient-based evidence varies across HTA topics. Currently, the syntheses are conducted in parallel with other evidence gathering which is partly due to aggressive timelines. However, CADTH is exploring whether this type of review should be done
earlier, perhaps during the scoping phase to better inform the entire assessment. Using QES to explore relevant patient aspects is a rapidly evolving aspect of CADTH’s work and has been very well accepted by expert committees.

**Patient input in TNF-alpha inhibitors (NICE)**

It is likely that HTA bodies and the patients and patient groups that take part in HTAs, may at times have different perspectives about how and when patient involvement added value to an HTA. An example is drawn from a case study prepared by a patient group, the National Ankylosing Spondylitis Society (NASS), following its participation in a National Institute for Health and Care Excellence (NICE) HTA of TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis (15). NASS recorded the case study to enable other patient groups to learn from their experience.

The case study suggests that to have impact, a patient group needs to undertake considerable work before, during and after the initial assessment. NASS identified the need to keep up to date with therapy developments in its areas, including monitoring the medical advisory board and the latest clinical research papers and attending conferences. NASS also gained a solid understanding of the needs of people living with ankylosing spondylitis in the UK by conducting surveys every three years with their members, taking 5000 calls per year on their helpline, speaking to members at an annual members’ day and awareness events around the UK and interacting through social media. This preparation enabled NASS to provide an informed response within the short timelines when NICE announced the appraisal.

NASS drew on its knowledge base when completing the NICE template for patient group submissions to provide information about the impact on daily life of ankylosing spondylitis, but also ran an online survey with their members during the submission period to identify patient views on specific issues, such as iv infusion and sequential treatment. For example, the online survey used closed questions to gather statistics such as the number of patients currently on anti TNF therapy and open questions which could be analysed to gain a greater understanding of the advantages and disadvantages of treatment options. The survey was open for four weeks and attracted 608 responses. When the data was analysed, it provided NASS with useful statistics, themes and illustrative quotes.

Following a review of the evidence and submissions, NICE published its draft recommendations in its Appraisal Consultation Document (16). At this point, NASS had 20 days to comment on the draft recommendations which included two important areas for people with ankylosing spondylitis that were negative. First, infliximab was not recommended for the treatment of ankylosing spondylitis. Secondly, treatment with another anti TNF therapy was not recommended for people whose disease had not responded to treatment with the first anti TNF therapy, or those who had an initial response which was then lost.

In response to the draft recommendations, NASS conducted another survey with members on these two issues, particularly seeking the views of people who had switched anti TNF therapies, reasons as to why they had switched, and how beneficial this switch had been. The survey was open for only eight days due to the consultation deadline, but attracted 858 responses which provided statistics and quotes to clarify patients’ experiences and needs.

From this data, NASS was able to provide a slide presentation (including graphs and quotes from patients) for the NICE expert committee on the sequential use of anti-TNF therapies and the specific people/populations who might benefit from infliximab because it was not a self-administered treatment. These included people with memory loss, learning disabilities, dexterity problems, or a fear of needles.
These real-life data resulted in the negative recommendations being changed as follows.

Extracts from the final guidance

*Patient evidence paragraphs (guidance 4.22, 4.23, 4.24)*

- There is also anecdotal evidence suggesting that a second or third TNF-alpha inhibitor can be clinically effective if the first has failed.
- [Infliximab] might benefit people with memory problems, learning disabilities, dexterity problems, or a fear of needles. (15)

*Patient input – submissions, surveys and representatives (CONITEC)*

In Brazil, community participation is stipulated as a right in the Brazilian Federal Constitution and other laws, including those related to the Brazilian Public Health System (SUS). The Law 12,401/2011 created the National Committee for Health Technology Incorporation (CONITEC) and formalized PPI in the SUS HTA process through:

- public consultations for all recommendations about the inclusion, exclusion or modification of health technologies;
- public hearings, depending on the assessment (not yet undertaken);
- the participation of the National Health Council, which represents citizens and users of SUS, as a member of CONITEC (17).

Usually, CONITEC recommendations are submitted for public consultation for 20 days, but consultation can be prolonged. Anyone can provide comments on the recommendations if they identify themselves.

In 2014, a consultation form specifically for the public was created to capture the patient and caregiver perspectives of the technologies being assessed. Currently, there are two forms for public consultation comments available online. The first, seeking technical and scientific information, is usually completed by health professionals, industry and the general public. The second aims to capture opinions or experiences and is completed by patients, caregivers and health professionals (18).

The number of submissions received from patients and the public is one measure of patient involvement impact (18). In 2014, CONITEC began to disseminate a list of upcoming public consultations on its website and e-mail lists and partner’s social media. This resulted in a more than 400% increase in submissions annually; from 2,584 submissions in 2014 to 13,619 submissions in 2015. This figure was influenced by two topics - beta interferon 1-a in multiple sclerosis (19) and cesarean section (20) - which attracted 4,846 submissions and 3,706 submissions respectively. However, an exponential increase can still be noticed if these two topics are excluded.

Between January 2012 and June 2017, CONITEC performed 219 public consultations, receiving more than 30,000 submissions with more than half of these from SUS users. Since 2015, CONITEC has produced summary versions of its technical reports for the public and patients in plain language to aid understanding of the reports and enable patients to contribute more easily. This tool may also have contributed to the increase in community participation.

To investigate patient needs and preferences, CONITEC began conducting patient surveys in 2015 to inform its Clinical Protocols and Therapeutic Guidelines (PCDT). By June 2017, 13 surveys had been completed. Patients provided information about their diseases and made suggestions, such as healthcare improvements, appeals for new technologies and aspects that in their perspective critically needed addressing in the PCDT.
In 2014 and 2015, patient representatives took part in CONITEC’s plenary sessions aimed at solving issues related to the use of technology including “Budesonide and Formoterol in aerosol for the treatment of asthma” (18). One of the patient representatives taking part in a plenary session, a guest patient representative of the Brazilian Association of Asthmatics (Associação Brasileira de Asmáticos - ABRA), reported the difficulties faced by patients to control the disease, the high cost of treatment and, most importantly, the educational process needed for safe and correct use of medicines. The patient representative ratified the similar efficacy of the analyzed technologies and identified education as the most important issue as patients were often unaware of how to correctly use medical devices in asthma.

**Conclusion**

**Reflections on the case studies**

These observations from people experienced in patient involvement in HTA bodies provide specific case studies that use different patient involvement approaches and reflect on their impact in HTA. The story from CONITEC describes increasing the number of written submissions from patients as a measure of impact and highlights the role patients can play in identifying issues that matter most to patients, such as education about the correct use of a health technology. The story teller makes a link between the implementation of communication tools – such as disseminating information about upcoming consultations and preparing plain language guides to technical reports – and achieving the impact of increased patient participation.

In the CADTH story, patient involvement was described as an important source of evidence to inform an assessment with patient-based evidence revealing patient behaviours when seeking treatment and using the health technologies, as well as educational needs. The story teller makes a link between conducting QES on patient needs and preferences and achieving the impact of adding information which can test assumptions and address gaps in the clinical and cost effectiveness evidence. This is consistent with findings that patient involvement can provide useful information in an HTA when there are uncertainties and gaps in the literature (21).

The SHTG story, demonstrates the value of using primary and secondary research into patients’ needs, preferences and experiences to determine the optimal use of a health technology. It highlights that secondary research may only identify condition specific information and that primary research may be needed to answer specific research questions relating to patients’ perspectives and experiences of using the health technology in the local health system. It suggests patient involvement can be especially valuable when there is a paucity of clinical and economic evidence and has an important role for HTAs of non-medicines and medicines. The storyteller makes the link between patient involvement and impact of the inclusion of recommendations in the HTA report which reflect their words, needs and preferences. Finally, this story teller links patient involvement with a wider impact on the HTA process with patient involvement requiring the development and incorporation of appropriate methodologies, influencing questions that can be asked and the evidence assessed in future HTAs.

The experience of NASS and NICE also points to the potential for patient involvement to enable HTAs to make more informed recommendations by providing data that was not available in the published literature. This story teller emphasised a link between the patient organizations preparation, responsiveness and ongoing involvement in the HTA and the impact of changing the recommendation to take account of the experiences of patients who would use the treatment, and the differing needs of patients with the same condition.
It is noteworthy, that although the NICE case study resulted in changing a negative recommendation for a medicine to a positive recommendation, the common theme to each example provided is that of greater information about patients’ lives leading to improved decisions about how and when a health technology is used. Additionally, while patient involvement is sometimes considered an additional cost and burden lacking methodology, these examples suggest that HTA bodies may make better informed decisions using documented practices such as patient submissions and robust methodologies such as QES.

Without patient involvement could SHTG have developed consensus guidance on the optimal use of antimicrobial wound dressings? Without patient involvement could CADTH and CONITEC have identified the most important issues for sleep apnea and asthmatic patients respectively? And without the data collected by NASS, how could NICE have identified sub-groups not identified in the clinical trials who could benefit from a treatment. As work continues to develop the tools to evaluate the impact of patient involvement in HTA, it may also be worth considering the impact of omitting patient involvement.

**Other evaluations of impact**

The term ‘impact’ lacks definition and is used interchangeably with influence in the literature. It can be linked with achieving a goal (5) or fulfilling a purpose which is evidenced by a range of outcomes such as the decisions made, behaviour changed and knowledge gained (24). While this paper focuses on a positive impact, unintended consequences and negative impacts are also an important part of measuring impact. Identifying the impact of patient involvement may depend on locating outcomes or actions “that can be credibly linked to” (24) the goal or intent of patient involvement. Furthermore, the stories presented in this paper are just one example of impact evaluation. Each HTA body uses other processes.

To understand the impact of patient involvement, HTA bodies need to document its use and influence (4). An evaluation of Danish HTAs points to how this information should be documented such as including a section on patient aspects in the HTA report to enable others to determine how patient aspects were addressed, the kind of data included and how it was generated, and if it was integrated in the conclusion (22). Similarly, all National Institute for Health Research (NIHR) projects require a section in their annual reports detailing how patients were involved and the difference it made (23) and the HTAi Values and Quality Standards for Patient Involvement in HTA requiring HTA bodies to report the influence of patient contributions on conclusions and decisions in each HTA forms part of the CADTH’s framework for patient engagement in HTA (13).

As SHTG rarely undertakes full HTAs it is not possible to fully evaluate the impact of patient involvement across these reports. However, the HTA report documents the methods for primary and secondary research into patient aspects, identifying key findings. The final recommendations then document whether they have arisen from the patient aspects section. Furthermore, each full HTA is evaluated according to a logic model that has been developed to guide all SHTG work. A new process for targeted patient involvement in more rapid HTAs has been developed and an evaluation framework process is being developed.

At CADTH, a recent independent evaluation of patient involvement in medicine HTAs, specifically the Pan-Canadian Oncology Drug Review, included interviewing expert committee members, agency staff and patient groups to explore different expectations for patient involvement and if these have been met (25). It also measured impact against set goals defined by the participants, rather than external criteria, to explore variable achievement of democratic and scientific goals.
At NICE, the impact of most patient involvement has not been routinely documented or evaluated; rather its contribution has been noted (how) when it has provided new insight, such as changing a comparator, or real-life data to answer a question in the absence of published (or existing) evidence. However, since February 2016, NICE has systematically captured the impact of patient input in two types of HTAs: the interventional procedures and ultra-orphan programmes. This is to identify the most effective methods of patient involvement, provide examples of what works well, and to inform feedback letters to patient organizations of their involvement and subsequently help strengthen any future involvement.

Meanwhile, in addition to other processes described in this paper, CONITEC has an ongoing partnership with the Oswaldo Cruz Foundation (Fiocruz) School of Governance in Health based in Brasilia to enable the systematic measurement of impact of the public and patient involvement (PPI) at all (local, regional and national) levels.

**Future use of impact stories**

Personal stories have a role to play in reflecting on the impact of patient involvement in HTA, enabling evidence to be collected on activities individuals link to patient involvement, potentially enabling a wider understanding of the construct of impact in patient involvement. Future research should explore stories of the impact of patient involvement in HTA that come from all stakeholders involved in HTA, particularly patients and their representative groups and HTA decision makers. This could consider short and long-term impacts and the way in which patient involvement changes HTA bodies and patient organizations, HTA processes and industry.

**References**

http://www.sst.dk/~media/ECAAC5AA1D6943BEAC96907E03023E22.ashx
http://www.iss.it/binary/eahi/cont/32_Hielkema_Full_text.pdf
http://www.healthcareimprovementscotland.org/his/idoc.ashx?docid=475ce1a5-fd38-4b3d-8f93-d83cdf7e1d9a&version=-1
Table 1 HTA bodies and speakers who took part in the workshop panels

<table>
<thead>
<tr>
<th>Panel 1: How/when research into patient aspects and patient-based evidence is making a difference to an HTA or HTAs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HTA body</strong></td>
</tr>
<tr>
<td>CADTH – Canadian Agency for Drugs and Therapies in Health</td>
</tr>
<tr>
<td>DÉFACTUM (Denmark)</td>
</tr>
<tr>
<td>AGENAS -National Agency for Regional Health Services (Italy)</td>
</tr>
<tr>
<td>SHTG - Scottish Health Technologies Group, Quality Improvement Scotland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Panel 2: How/when patient participation is making a difference to an HTA or HTAs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HTA body</strong></td>
</tr>
<tr>
<td>PBAC - Pharmaceutical Benefits Advisory Committee (Australia)</td>
</tr>
<tr>
<td>CONITEC - National Committee for Health Technology Incorporation (Brazil)</td>
</tr>
<tr>
<td>NICE - National Institute for Health and Care Excellence (England)</td>
</tr>
<tr>
<td>CDE - Division of Health Technology Assessment, Center for Drug Evaluation (Taiwan)</td>
</tr>
</tbody>
</table>
Table 2: Summary of organizations and their processes

<table>
<thead>
<tr>
<th>Organization</th>
<th>Canadian Agency for Drugs and Technologies in Health</th>
<th>National Committee for Health Technology Incorporation (Comissão Nacional de Incorporação de Tecnologias no SUS)</th>
<th>The National Institute for Health and Care Excellence</th>
<th>Scottish Health Technologies Group, Healthcare Improvement Scotland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviation</td>
<td>CADTH</td>
<td>CONITEC</td>
<td>NICE</td>
<td>SHTG</td>
</tr>
<tr>
<td>Jurisdiction</td>
<td>Canada</td>
<td>Brazil</td>
<td>England</td>
<td>Scotland</td>
</tr>
<tr>
<td>Function</td>
<td>To provide health care decision-makers with objective evidence to inform decisions about the optimal use of health technologies&lt;sup&gt;1&lt;/sup&gt;</td>
<td>To advise the Brazilian Ministry of Health in decisions related to the incorporation, exclusion or change of medicines, products and procedures in the Brazilian Public Health System (SUS).&lt;sup&gt;2&lt;/sup&gt;</td>
<td>To provide national guidance and advice to improve health and social care, including assessing the clinical and cost effectiveness of health technologies, such as new pharmaceutical and biopharmaceutical products, procedures, devices and diagnostic agents. To ensure that all National Health Service patients have equitable access to the most clinically and cost-effective treatments that are viable.&lt;sup&gt;3&lt;/sup&gt;</td>
<td>To provide NHSScotland boards with advice on the evidence about the clinical and cost effectiveness of existing and new technologies – excluding medicines - likely to have significant implications for patient care in Scotland. &lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th><strong>Patient involvement approaches</strong> (bold indicates used in story)</th>
<th>Stakeholder feedback on included studies, draft report and recommendations</th>
<th>Public consultation (online form for public, patients and caregivers)</th>
<th>Scoping consultation with patient groups</th>
<th>Open topic proposal process</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patient group submissions (individual patient submissions if no group)</td>
<td>Surveys - Clinical Protocols and Therapeutic Guidelines</td>
<td>Patient group and patient expert submissions</td>
<td>Patient group submissions</td>
</tr>
<tr>
<td></td>
<td>Literature synthesis, QES</td>
<td>Patient representatives (plenary sessions).</td>
<td>Lay member and invited patient expert participation in committee meetings</td>
<td>Targeted patient group consultation</td>
</tr>
<tr>
<td></td>
<td>One or two public, no patient, expert committee members5</td>
<td></td>
<td>Open, public meetings</td>
<td>Public Partner membership of SHTG</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Consultation on draft recommendations</td>
<td>expert advisory committee membership by invitation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Appeal</td>
<td>Open, public meetings</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Plain language reports</td>
<td>Primary patient aspects research</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Patient groups consulted regarding need to review guidance6</td>
<td>Literature synthesis, QES</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lay member and invited patient expert participation in committee meetings</td>
<td>Plain language report7</td>
</tr>
</tbody>
</table>

| **Type of HTA/s in story** | Optimal Use, Device (14 months) | Multiple including rapid medicine HTA (180 days) and clinical guidelines | Multiple technology appraisal (60 weeks) | Full, non-medicines HTA (approximately 1.5-2 years) |

| **Story topic** | Obstructive sleep apnea | Multiple | TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis | Antimicrobial wound dressings in patients with chronic leg ulcers |

---


| Result | • Evidence about patient behaviours and need which addressed critical gaps | • Increased participation  
• Information about patient’s information needs | Change to recommendation based on patient group identified sub-group not identified in clinical trials. | • Evidence of outcomes valued by patients and patient need enabled a guideline to be produced  
• Challenge to organization’s concept of evidence  
• Work to develop processes to enable robust patient-based evidence to be used in rapid timelines. |
Conflict of interest
Ms Single reports other from Springer Nature, personal fees from Patient Voice Initiative, outside the submitted work; and is an active member of HTAi’s Patient and Citizen Involvement Interest Group which supported (non-financial) the workshop where these case studies were discussed.

Dr. Facey reports personal fees from Sanofi, personal fees from Novartis, personal fees from Health Technology Wales, NHS HTA body, personal fees from Allergan, personal fees from Celgene, personal fees from Janssen, personal fees from Roche, personal fees from UCB, personal fees from Takeda, personal fees from International Plasma Protein (industry umbrella body), personal fees from Scottish Health Technologies Group (NHS HTA body), personal fees from FIPRA, personal fees from Eli Lilly and Company, personal fees from AIFP (Industry umbrella organisation in Czech Republic), other from HTAi, other from ISPOR, other from EUPATI, grants from EC H2020 grant for university research for 2 days per week outside the submitted work; .